Perspectives in Lung Cancer

Scientific Agenda

Friday, 5 March 2010

8:15	Welcome and introduction Pieter E. Postmus, MD, PhD

Session I: The changing epidemiology of lung cancer
Moderators: Silvia Novello, MD, PhD and Egbert F. Smit, MD, PhD

8:30	Molecular epidemiology of lung cancer Paolo Boffetta, MD,MPH
8:50	Changing demographics of smoking and its effects during therapy Egbert F. Smit, MD, PhD
9:10	Women and lung cancer Silvia Novello, MD, PhD
9:30	Smoking cessation techniques: An update Jacques Cornuz, MD, MPH
9:50	Clinical case of never smoker patient Egbert F.Smit, MD, PhD
10:10	Coffee break

Session II: Diagnosis and staging
Moderators: Peter Goldstraw, MD and Giorgio V. Scagliotti, MD, PhD

10:40	Evaluation of the pulmonary solitary nodule Maurizio Zompatori, MD
11:20	Early detection of lung cancer Robert J. Van Klaveren, MD, PhD
11:40	Diagnostic challenges for thoracic pathologist Keith Kerr, FRCPath, FRCPEd
12:00	The implementation of the new IASLC-UICC TNM staging system Peter Goldstraw, MD
12:20	Lunch symposium supported by Eli Lilly and Company From controversy to consensus on the treament of advanced stage NSCLC

Session III: Diagnosis and treatment of the early NSCLC
Moderators: Christian Manegold, MD and
Pieter E. Postmus, MD, PhD

14:20	Physiological assessment of patients with resectable NSCLC Kristiaan Nackaerts, MD, PhD
14:40	Mediastinal staging: Surgical pro Paul E. Y. Van Schil, MD, PhD
15:00	Mediastinal staging: Surgical contra Stefano Gasparini, MD
15:20	Adjuvant systemic therapy Christian Manegold, MD
15:40	Is the neo-adjuvant approach better than adjuvant approach? Virginie Westeel, MD
16:00	Coffee break

Session IV: New agents in lung cancer
Moderators: Luis Paz Ares, MD and Johan F. Vansteenkiste, MD, PhD

16:30	Agents against type 1 insulin-like growth factor receptor (IGF-R1) Luis Paz Ares, MD
16:50	Apoptotic agents Dean Fennell, MD, PhD
17:10	HDAC and PARP inhibitors Suresh S. Ramalingam, MD
17:30	Vaccines: Any expectations? Johan F. Vansteenkiste, MD, PhD
17:50	Summary of the day
18:00	Adjourn

Saturday, 6 March 2010

8:00	Welcome and introduction Giorgio V. Scagliotti, MD, PhD

Session V: Radiotherapy in lung cancer
Moderators: Pieter E.Postmus, MD, PhD and Allan Price, MD

8:10	Stereotactic radiotherapy in early NSCLC Umberto Ricardi, MD, PhD
8:30	Radiotherapy in locally advanced NSCLC Allan Price, MD
8:50	Palliative radiotherapy Umberto Ricardi, MD, PhD
9:10	Prophylactic brain irradiation in lung cancer Cécile Le Pechoux, MD
9:30	Clinical case
9:50	Coffee break

Session VI: Changing the treatment paradigms in front line metastatic NSCLC
Moderators: Giorgio V. Scagliotti, MD, PhD and
Thomas G. Sutedja, MD, PhD, FCCP

10:20	Histology in the therapeutic decision-making process Giorgio V. Scagliotti, MD, PhD
10:40	Anti-angiogenic agents: Where we are? Martin Reck, MD
11:00	Debate: Maintenance chemotherapy – cytotoxic agents versus targeted agents Cytotoxics - Suresh S. Ramalingham, MD Targeted therapies – Federico Cappuzzo, MD
11:40	Interventional bronchology in the management of NSCLC Thomas G. Sutedja, MD, PhD, FCCP
12:00	Lunch symposium supported by Roche Expanding treatment options across lung cancer management

Session VII: Where do we stand with biomarkers?
Moderators: Lucio Crinò, MD and Martin Reck, MD

14:00	How to design a clinical study using biomarkers Richard Stephens
14:20	Molecular predictors of response and resistance to EGFR-inhibiting agents Lucio Crino, MD
14:40	Pharmacogenomic approaches Luis Paz Ares, MD
15:00	Third line and beyond Wilfred Eberhardt, MD

Session VIII: Mesothelioma
Moderators: Pieter E. Postmus, MD, PhD and
Egbert F. Smit, MD, PhD

15:20	Diagnosis and staging Paul Baas, MD, PhD
15:40	Treatment of mesothelioma Jan P. van Meerbeck, MD, PhD
16:00	Clinical case
16:20	Adjourn

Perspectives in Lung Cancer